

Final PROGRAM



CTAD **2026**
Clinical Trials on Alzheimer's Disease

**November
16-19, 2026
Boston, MA (USA)**

www.ctad-alzheimer.com
Email: ctad@ant-congres.com

JPAD
THE JOURNAL
OF PREVENTION
OF ALZHEIMER'S
DISEASE



TABLE OF CONTENTS

Organizing & Scientific Committees	03
Editorial	04
Lifetime Achievement Award	05
Keynotes	06
Scientific Sessions	07
Monday, November 16	07
Tuesday, November 17	09
Wednesday, November 18	13
Thursday, November 19	18

CTAD Organizing Committee and Scientific Committee

Susan ABUSHAKRA (San Francisco, United States); **Paul AISEN** (San Diego, United States)*; **Rebecca E. AMARIGLIO** (Boston, United States); **Patricia ANDREWS** (Nashville, United States); **Sandrine ANDRIEU** (Toulouse, France)*; **Davide ANGIONI** (Toulouse, France); **Laura D. BAKER** (Winston-Salem, United States); **Randall J. BATEMAN** (St. Louis, United States); **Karim BENNY** (Montpellier, France); **Ram BISHNOI** (Tampa, United States); **Kaj BLENNOW** (Molndal, Sweden); **Merce BOADA** (Barcelona, Spain); **Marc CANTILLON** (Livingston, United States); **Maria CARRILLO** (Chicago, United States); **Mathieu CECCALDI** (Marseille, France); **Suzanne CRAFT** (Winston-Salem, United States); **Lucia CRIVELLI** (Buenos Aires, Argentina); **Jeffrey CUMMINGS** (Las Vegas, United States); **Steven DEKOSKY** (Gainesville, United States); **Michael C. DONOHUE** (San Diego, United States); **Rachelle DOODY** (Houston, United States); **Bruno DUBOIS** (Paris, France); **Howard FELDMAN** (San Diego, United States); **Howard FILLIT** (New York, United States); **Nick FOX** (London, UK); **Kristian Steen FREDERIKSEN** (Copenhagen, Denmark); **Giovanni B. FRISONI** (Brescia, Italy); **Serge GAUTHIER** (Montreal, Canada); **Joshua GRILL** (Los Angeles, United States); **Michael GRUNDMAN** (San Diego, United States); **Harald HAMPEL** (Nutley, United States); **Oskar HANSSON** (Lund, Sweden); **Tobias HARTMANN** (Homburg, Germany); **Jakub HORT** (Prague, Czech Republic); **Takeshi IWATSUBO** (Tokyo, Japan); **Frank JESSEN** (Cologne, Germany); **Ara KHACHATURIAN** (Washington DC, United States); **Zaven KHACHATURIAN** (Washington DC, United States); **Miia KIVIPELTO** (Stockholm, Sweden); **Yan LI** (St. Louis, United States); **Jorge J. LLIBRE GUERRA** (St. Louis, United States); **Constantine G. LYKETSOS** (Baltimore, United States); **Gad A. MARSHALL** (Boston, United States); **Adam MECCA** (New Haven, United States); **Lefkos T. MIDDLETON** (London, UK)*; **José Luis MOLINUEVO** (Valby, Denmark); **Kyra O'BRIEN** (Philadelphia, United States); **Claire PAQUET** (Paris, France); **Robert PERNECZKY** (Munich, Germany); **Ronald PETERSEN** (Rochester, United States); **Elif PINAR COSKUN** (Lexington, United States); **Michael S. RAFII** (San Diego, United States); **Rema RAMAN** (San Diego, United States); **Craig W. RITCHIE** (Edinburgh, UK); **Robert RISSMAN** (San Diego, United States); **Marwan SABBAGH** (Phoenix, United States); **Stephen SALLOWAY** (Providence, United States); **Pascual SANCHEZ-JUAN** (Madrid, Spain); **Nikolaos SCARMEAS** (New York, United States); **Rachel SCHINDLER** (New York, United States); **Philip SCHELTENS** (Amsterdam, NL); **Lon SCHNEIDER** (Los Angeles, United States); **Eric SIEMERS** (Indianapolis, United States); **Sietske SIKKES** (Amsterdam, The Netherlands); **Yong SHEN** (Hefei, China); **Jiong SHI** (Hefei, China); **Irina SKYLAR-SCOTT** (Stanford, United States); **Heather SNYDER** (Chicago, United States); **Maria SOTO** (Toulouse, France); **Reisa SPERLING** (Boston, United States)*; **Yaakov STERN** (New York, United States); **Duygu TOSUN** (San Francisco, United States); **Jacques TOUCHON** (Montpellier, France)*; **Maileen ULEP** (Las Vegas, United States); **Wiesje van Der FLIER** (Amsterdam, The Netherlands); **Christopher H. VAN DYCK** (New Haven, United States); **Bruno VELLAS*** (Toulouse, France); **Prashanthi VEMURI** (Rochester, United States); **Michael W. WEINER** (San Francisco, United States)* **Donna M. WILCOCK** (Indianapolis, United States); **Bengt WINBLAD** (Stockholm, Sweden); **Kirsten WRIGHT** (Portland, United States); **Jin-Tai YU** (Shanghai, China)

*Organizing Committee Member

Join Us at CTAD26: Advancing Alzheimer's Disease Clinical Research Together

The 19th Clinical Trials on Alzheimer's Disease (CTAD) Conference will convene in Boston, USA, from November 16–19, 2026. For those of us who have watched our field transform over the past two decades, there is something fitting about returning to Boston — a city that has long been at the heart of Alzheimer's research — at what feels like a genuinely pivotal moment.

Since its founding in 2008, CTAD has grown into the premier global forum dedicated exclusively to Alzheimer's disease clinical research. What has always set CTAD apart is its format: all sessions take place in a single main ballroom, so that every investigator, clinician, industry scientist, and regulatory expert in attendance shares the same presentations and the same conversations. In a field where translation from bench to bedside depends on true interdisciplinary exchange, that shared experience matters. Some of the most consequential discussions I have witnessed in our field have happened in the hallways and roundtables during CTAD.

CTAD25 in San Diego offered a comprehensive picture of where the Alzheimer's clinical trials now stand. More than 2,850 international experts gathered to examine emerging data and evolving strategies across the full spectrum of Alzheimer's research. Sessions addressed disease-modifying therapies, gene- and cell-based approaches, vaccines, digital tools, and multimodal interventions, reflecting how far we have come but also how much remains to be done.

CTAD26 in Boston will carry that momentum forward. The questions we will be asking are more focused than even a few years ago: How do we define who needs to be treated with what and when? Who will benefit most from early intervention? How do we optimize combination approaches, not just tau and amyloid but including other emerging therapeutic mechanisms? What do biomarkers tell us about individualized disease trajectories that can inform more efficient trial design? These are the conversations that CTAD seeks to nurture and more...

I hope you will join us in Boston this November. We have made tremendous progress in Alzheimer's disease research due to the unwavering commitment of this community, and the open, cross-disciplinary collaborations that CTAD is designed to foster. There is no better place to continue that work than here in Boston, and we look forward to welcoming you all.




Reisa Sperling, MD

Harvard Medical School,
Brigham and Women's Hospital
Boston, MA (United States)

CTAD 2026

Lifetime Achievement Award

This year, the Lifetime Achievement Award in Alzheimer's Disease Therapeutic Research is awarded to Jeffrey Cummings, MD, in recognition of his foundational contributions to clinical trial methodology, drug development frameworks, and his decades of leadership in advancing the field through the annual Alzheimer's disease drug development pipeline analyses.



Jeffrey Cummings, MD, ScD

Joy Chambers-Grundy Professor of Brain Science

Director of the Chambers-Gundy Center for Transformative Neuroscience

Co-Director of the Pam Quirk Brain Health and Biomarker Laboratory, Department of Brain Health, School of Integrated Health Sciences, University of Nevada Las Vegas (UNLV)

Biography

UNLV research professor Jeffrey L. Cummings is a neurologist globally recognized for his contributions to Alzheimer's research, drug development, and clinical trials. He serves as the Joy Chambers-Grundy professor of brain science and director of the Chambers-Grundy Center for Transformative Neuroscience at the Kirk Kerkorian School of Medicine's Department of Brain Health.

Dr. Cummings leads the UNLV Clinical Trials Observatory, the world's only research observatory devoted exclusively to analyzing the pipeline of Alzheimer's drugs in clinical trials to better inform drug development decisions. He also heads a biomarker observatory, which captures and categorizes emerging information on blood tests, brain scans, and digital devices related to Alzheimer's disease.

Prior to joining UNLV in 2019, Dr. Cummings served as founding director of the Cleveland Clinic Lou Ruvo Center for Brain Health in Las

Vegas, as well as two UCLA entities — the Mary S. Easton Center for Alzheimer's Disease Research, and the Deane F. Johnson Center for Neurotherapeutics.

Named a "Rock Star of Science" by Gentleman's Quarterly, Dr. Cummings — a fellow of the American Academy for the Advancement of Science — has published 43 books and more than 900 peer-reviewed articles on neuropsychiatry, Alzheimer's disease, and clinical trials.

His numerous recognitions for his scientific and leadership contributions include the American Association of Geriatric Psychiatry's Distinguished Scientist Award, Melvin R. Goodes Prize for Excellence in Drug Development from the Alzheimer's Drug Discovery Foundation, Society for Behavioral and Cognitive Neurology's Lifetime Achievement Award, and the national Alzheimer's Association's Bengt Winblad Lifetime Achievement Award. In 2024, he was ranked by ScholarGPS as the world's top scholar for his lifetime contributions in the areas of dementia and drug development.

KEYNOTE

New Molecules in Phase 2b — Proof of Concept and Beyond

Monday, November 16 • 3:25 p.m. — 3:50 p.m.

CTAD 2026 Keynotes



A Glimpse of the Future: How Diagnostics, Therapies, Trials, and Concepts of Prevention Must Evolve

Geoffrey A. Kerchner, MD, Vice President and Global Head of Neurodegeneration, F. Hoffmann-La Roche, Ltd., Basel (Switzerland)

Geoffrey A. Kerchner, MD, PhD is a neurologist and neuroscientist serving as Vice President and Global Head of Neurodegeneration at F. Hoffmann-La Roche, Ltd., in Basel, Switzerland, where he oversees all late-stage clinical development efforts in Alzheimer's, Parkinson's, and Huntington's diseases. Over his career, Dr. Kerchner has contributed to the fight against Alzheimer's disease as a basic scientist, a clinical neuroimaging scientist, a clinician, a patient advocate, and a clinical trial site investigator before moving to Genentech/Roche in 2015. There, he led clinical development teams for semorinemab and gantenerumab, among other programs, before moving into leadership positions, first as VP and Head of Early Development in Neuroscience and Rare Diseases and then in his current role. Dr. Kerchner studied at Harvard College (AB summa cum laude), Washington University School of Medicine (MD, PhD), and UCSF (residency and fellowships), and served on the faculty at Stanford University School of Medicine.



Integration of Fluid Imaging and other Multimodal Biomarkers towards Optimizing Disease Understanding and New Therapeutics

Susan Landau, PhD, Research Neuroscientist, Helen Wills Neuroscience Institute, University of California, Berkeley, CA (United States)

Dr Landau's research focuses on brain changes that occur in healthy aging and Alzheimer's disease. She uses a variety of neuroimaging techniques, other biomarkers, and health information to understand the neurophysiological processes underlying cognitive decline in Alzheimer's disease and related dementias. Her research has a particular emphasis on the roles of amyloid and tau, measured with positron emission tomography (PET), and neurodegeneration, measured with magnetic resonance imaging (MRI).

She is the principal investigator of POINTER Imaging study, an ancillary study to the U.S. Study to Protect Brain Health Through Lifestyle Intervention to Reduce Risk (U.S. POINTER) trial. This 2-year clinical trial is examining the influence of multidomain lifestyle interventions on brain changes in at-risk older individuals across the U.S. She also oversees PET pipeline development and analysis in multisite longitudinal studies including the Alzheimer's Disease Neuroimaging Initiative (ADNI), the ADNI Vietnam War Veterans study, the ADNI Late Life Depression study, and the Standardized Centralized Alzheimer's & Related Dementia Neuroimaging (SCAN) study. She has led curation and quantification of over 8000 PET images acquired with a variety of PET tracers and has made this data available to the scientific community for research, education, and clinical trial development. Dr. Landau received the Human Amyloid Imaging Christopher Clark Award in 2018.



Beyond Amyloid and Tau: Roles of Proteomics in Clinical Trials

Allan Levey, MD, PhD, Professor of Neurology, Emory University's School of Medicine, Director, Emory's Alzheimer's Disease Research Center, Emory University, Atlanta, GA (United States)

Allan Levey, MD, PhD, is a professor in the Department of Neurology at Emory University's School of Medicine, as well as the director of Emory's Alzheimer's Disease Research Center. He has secondary faculty appointments in the Departments of Pharmacology, Psychiatry and Behavioral Sciences.

Levey is an internationally recognized expert in neurodegenerative disorders. His work has contributed to understanding the brain systems and mechanisms involved in disorders such as Alzheimer's and Parkinson's diseases, as well as in identifying molecular targets for new therapeutic strategies. He has more than 250 research publications and has won several awards, including the Derek Denny-Brown Neurological Scholar Award from the American Neurological Association, the Heikkila Research Scholar Award from the National Parkinson Foundation, the Health Advancement Research Award from Community Health Charities and the Team Hope Award for Medical Leadership from the Huntington's Disease Society of America. In addition, he was inducted into the Johns Hopkins Society of Scholars.

Levey consistently has been listed among one of the Best Doctors in America. His research interests include fundamental research into the cause of Alzheimer's disease and related neurodegenerative disorders, and development of new biomarkers and treatments.

● Monday, November 16

2:15 p.m.
3:15 p.m.

POSTER WALKING TOUR

3:15 p.m.
3:25 p.m.

Welcome Ceremony & CTAD Lifetime Achievement Award in Alzheimer's Disease Therapeutic Research

Presented to Jeffrey Cummings, MD, in recognition of his foundational contributions to clinical trial methodology, drug development frameworks, and his decades of leadership in advancing the field through the annual Alzheimer's disease drug development pipeline analyses.

Introduction by the CTAD Organizing Committee

Reisa Sperling, Brigham and Women's Hospital Harvard Medical School, Boston (United States)

Paul Aisen, Alzheimer's Therapeutic Research Institute, University of Southern California, San Diego, CA (United States)

Sandrine Andrieu, Toulouse University Hospital and INSERM 1295, Toulouse (France)

Rachelle Doody, Houston, TX (United States)

Lefkos Middleton, Imperial College, London (United Kingdom)

Jacques Touchon, Montpellier University, Montpellier (France)

Bruno Vellas, IHU HealthAge, Toulouse University, Toulouse (France)

Mike Weiner, UCSF, San Francisco, CA (United States)

3:25 p.m.
3:50 p.m.

KEYNOTE 1

New Molecules in Phase 2b – Proof of Concept and Beyond

Jeffrey Cummings University of Nevada Las Vegas (UNLV), Las Vegas, NV (United States)

Introduction: Bruno Vellas, IHU HealthAge, Toulouse University, Toulouse (France)

3:50 p.m.
4:50 p.m.

ORAL COMMUNICATIONS

3:50 p.m.

OC1 Top-Line Results of SINGER: A Two-Year Randomized Controlled Trial of Multidomain Lifestyle Intervention to Prevent Cognitive Decline

Kwong Hsia Yap¹, Liang Shen², David Matchar^{3,4}, Helen Zhou^{5,6}, Mitchell Kim Peng Lai⁷, Xin Xu⁸, Cynthia Huijun Chen⁹, Laura Baker¹⁰, Miia Kivipelto^{11,12,13}, Nagaendran Kandiah¹⁴, Christopher Chen^{1,7}

¹Memory, Ageing and Cognition Centre (MACC), Department of Pharmacology, Yong Loo Lin School of Medicine, National University of Singapore - Singapore (Singapore), ²Singapore Clinical Research Institute - Singapore (Singapore), ³Health Services and Systems Research Programme, Duke-NUS Medical School - Singapore (Singapore), ⁴Division of General Internal Medicine, Department of Medicine, Duke University, Durham - North Carolina (United States), ⁵Centre for Sleep and Cognition, Yong Loo Lin School of Medicine, National University of Singapore - Singapore (Singapore), ⁶Department of Electrical and Computer Engineering, National University of Singapore, - Singapore (Singapore), ⁷Department of Pharmacology, Yong Loo Lin School of Medicine, National University of Singapore - Singapore (Singapore), ⁸School of Public Health and the Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, - Zhejiang (China), ⁹Saw Swee Hock School of Public Health, National University of Singapore - Singapore (Singapore), ¹⁰Department of Internal Medicine, Wake Forest University School of Medicine, Winston-Salem - North Carolina (United States), ¹¹Department of Neurobiology, Care Sciences and Society, Division of Clinical Geriatrics, Center for Alzheimer Research, Karolinska Institutet, - Stockholm (Sweden), ¹²Ageing Epidemiology Research Unit, School of Public Health, Imperial College London - London (United Kingdom), ¹³Institute of Public Health and Clinical Nutrition, University of Eastern Finland - Kuopio (Finland), ¹⁴Dementia Research Centre (Singapore), Lee Kong Chian School of Medicine, Nanyang Technological University - Singapore (Singapore)

4:05 p.m.

OC2 POLARIS-AD: A Global Phase 3 Trial of AR1001 in Early Alzheimer's Disease: Efficacy Outcomes at 52 Weeks and Safety Through the Extension Phase

Sharon Sha¹, Alireza Atri², Fernando Melgar-Somoza³, Marzena Zboch⁴, Do Hoon Kim⁵, Yi Tang⁶, Jennifer Lynch⁷, Howard Chertkow⁸, Sangyun Kim⁹, David Greeley¹⁰, James Rock¹¹, Fred Kim¹¹, Tianyang Xi¹¹, Jai Jun Choung¹¹

¹Stanford - Palo Alto (United States), ²Banner Sun Health Research and Banner Alzheimer's Institutes - Sun City (United States), ³Melgar-Caro MedCenter and Community Research - Miami (United States), ⁴Wroclawskie Centrum Alzheimerowskie - Wroclaw (Poland), ⁵Chuncheon Sacred Heart Hospital - Chuncheon (Republic of Korea), ⁶Xuanwu Hospital Capital Medical University - Beijing (China), ⁷Glasgow NeuroClin - Motherwell (United Kingdom), ⁸Baycrest Centre for Geriatric Care - Ontario (Canada), ⁹Seoul National University College of Medicine - Seoul (Republic of Korea), ¹⁰Northwest Neurological - Spokane (United States), ¹¹Aribio Co., Ltd - San Diego (United States)

4:20 p.m.

OC3 Ultrasensitive Immunoassay for Plasma eMTBR-243 Quantification

Alpana Singh¹, Marisa Denkinger¹, Geidy E. Serrano¹, Thomas G. Beach¹, Eric M. Reiman², Shorena Janelidze³, Oskar Hansson³, Niklas Mattsson-Carlsson³, Pedro Rosa Neto⁴, Nicholas Ashton¹

¹Banner Sun Health Research Institute - Sun City (United States), ²Banner Alzheimer's Institute - Phoenix (United States), ³Lund University - Lund (Sweden), ⁴UT Southwestern Medical Center - Austin (United States)

4:35 p.m.

OC4 Plasma p-tau217 outperforms neuroimaging biomarkers in predicting the risk of cognitive impairment in a multi-cohort study

Colin Birkenbihl¹, Madison Cuppels¹, Diana Townsend¹, Gillian Coughlan¹, Mabel Seto¹, Jane Brown¹, Michael Properzi¹, Annie Li¹, Bryan James², Robert Rissman³, Melissa Petersen⁴, Tobey Betthausen⁵, Doreen Rentz¹, Reisa Sperling¹, Rachel Buckley¹

¹Mass General Brigham - Boston (United States), ²Rush Alzheimer's Disease Center - Chicago (United States), ³University of Southern California - Los Angeles (United States), ⁴University of North Texas - Fort Worth (United States), ⁵University of Wisconsin-Madison - Madison (United States)

4:50 p.m.

5:30 p.m.

SYMPOSIUM 1

Visualizing the Brainshuttle™: Pioneering neuroimaging and mechanistic insights of amyloid clearance with trontinemab

Chair: Tammie L.S. Benzinger, Washington University in St. Louis -St. Louis, Missouri, (United States)

Presentation 1 Trontinemab in Alzheimer's disease – novel pharmacodynamic insights from the ongoing Phase Ib/IIa Brainshuttle™ AD study

Luka Kulic, F. Hoffmann-La Roche Ltd - Basel (Switzerland)

Presentation 2 Advanced imaging results from the Brainshuttle™ AD study with trontinemab in Alzheimer's disease

Gregory Klein, F. Hoffmann-La Roche Ltd - Basel (Switzerland)

Presentation 3 Brain delivery and distribution of the novel Brainshuttle™ Aβ-targeting antibody trontinemab in participants with Alzheimer's disease measured with ⁸⁹Zr positron emission tomography

Elsmarieke Van De Giessen, Amsterdam UMC, Vrije Universiteit - Amsterdam (The Netherlands)

5:30 p.m.

6:15 p.m.

ORAL COMMUNICATIONS

5:30 p.m.

OC5 Agentic Artificial Intelligence in Alzheimer's Disease Clinical Trials: From Data-Driven Discovery to Adaptive Design Optimization and Statistical Validation

Randall BATEMAN, Eric MCDADE, Yan LI, Guoqiao WANG

Washington University in St Louis, St Louis, United States

5:45 p.m.

LB01 Spectris Treatment in Mild-to-Moderate Alzheimer's Disease: Topline Results and Secondary Analyses From the HOPE Pivotal Study

Roy HAMILTON¹, Ralph KERN², Robbert ZUSTERZEEL², Marwan SABBAGH³

¹Department of Neurology, University of Pennsylvania, Philadelphia, United States, ²Cognito Therapeutics Inc., Cambridge, United States, ³Barrow Neurological Institute, Phoenix, United States

6:00 p.m.

OC6 Long-Term Outcomes with Lecanemab in Early Alzheimer's Disease: Initial Findings Through 60-Months of Clarity AD Open-Label Extension

Christopher VAN DYCK¹, David LI², Michio KANEKIYO², Shobha DHADDA², Michelle GEE³, Steven HERSCH², Michael IRIZARRY², Lynn KRAMER²

¹Yale University School of Medicine, New Haven, United States, ²Eisai Inc., Nutley, United States, ³Eisai Ltd., Hatfield, United Kingdom

6:15 p.m.

7:15 p.m.

CTAD WELCOME RECEPTION with the Support of the Alzheimer's Association



● Tuesday, November 17

7:30 a.m.
8:30 a.m.

POSTER WALKING TOUR

8:30 a.m.
9:10 a.m.

SYMPOSIUM 2

When Target Engagement Is Not Enough: Lessons from Posdinemab on Bridging Tau Biology to Clinical Outcomes

Chair: Fiona Elwood, Johnson & Johnson, Cambridge, MA, USA

Presentation 1 Spatial Determinants of Posdinemab's Effect on Tau PET

Ziad S. Saad, Johnson & Johnson, San Diego, CA (United States)

Presentation 2 CSF and Plasma Biomarker Changes After Anti-Tau Therapy: Fluid Biomarker Results from the Autonomy Phase 2 Clinical Trial

Gallen Triana-Baltzer, Johnson & Johnson, San Diego, CA (United States)

Presentation 3 Biomarker Associations with Cognition: Results from the Autonomy Phase 2 Clinical Trial

Gil D. Rabinovici, University of California, San Francisco (UCSF) - San Francisco, CA (United States)

9:10 a.m.
9:35 a.m.

KEYNOTE 2

A Glimpse of the Future: How Diagnostics, Therapies, Trials, and Concepts of Prevention Must Evolve

Geoffrey A. Kerchner, MD, Vice President and Global Head of Neurodegeneration, F. Hoffmann-La Roche, Ltd., Basel (Switzerland)

Introduction: Reisa Sperling, Brigham and Women's Hospital Harvard Medical School - Boston (United States)

9:35 a.m.
10:35 a.m.

ORAL COMMUNICATIONS

9:35 a.m.

OC7 Efficacy and Safety of Remlifanserin in Patients With Alzheimer's Disease Psychosis

Sanjeev Pathak¹, Clive Ballard², Jeffrey Cummings³, Samantha Friend⁴, Becky Howell¹, Christine Murphy⁴, Xiaoshu Feng¹, Mona Darwish¹, Bryan Dirks¹

¹Acadia Pharmaceuticals Inc. - Princeton (United States), ²University of Exeter Medical School - Exeter (United Kingdom), ³Kirk Kerkorian School of Medicine, University of Nevada - Las Vegas (United States), ⁴Acadia Pharmaceuticals Inc. - San Diego (United States)

9:50 a.m.

OC8 Clinical Evidence for Disease Modification by Amyloid-Targeting Antibodies

Lon Schneider¹, Guoqiao Wang², Richard Kennedy³, Gary Cutter³, Robert Howard⁴

¹USC Keck School of Medicine - Los Angeles (United States), ²Washington University in St. Louis - St. Louis (United States), ³University of Alabama, Birmingham - Birmingham (United States), ⁴University College London - London (United Kingdom)

10:05 a.m.

OC9 Topline results from the Phase 2b PRIus-AD trial: Safety and efficacy of oral PRI-002 in early AD

Oliver Peters^{1,2}, Dagmar Jürgens^{2,3}, Gerhard Tischler³, Tina Bartsch³, Lorenzo Bulli³, Katja Lindner³, Julie-Anne Gabelich³, Julia Post-Schulz³, Gunther Kauselmann^{2,3}, Knut Adermann^{2,3}, Kathrin Zeiger³, Alexander Brener³, Dieter Willbold^{2,4}

¹Charité - Universitätsmedizin Berlin - Berlin (Germany), ²Priavoid - Düsseldorf (Germany), ³PRInnovation - Düsseldorf (Germany), ⁴Institut für Pysikalische Biologie, Heinrich-Heine Universität Düsseldorf - Düsseldorf (Germany)

10:20 a.m.

OC10 Sex Differences in Plasma p-tau217, Amyloid- β , and Tau-PET in Cognitively Unimpaired Adults from the AHEAD International Screening Cohort

Gillian Coughlan¹, Madison Cuppels¹, Aaron Schultz¹, Keith Johnson¹, Robert Rissman², Doris Molina-Henry², Michael Donohue², Oliver Longford², Paul Aisen², Joel Braunstein³, Michael Irizarry⁴, Shobha Dhadda⁴, Rachel Buckley¹, Reisa Sperling¹, Ahead 3-45 Study Team⁵

¹Mass General Brigham, Department of Neurology - Boston (United States), ²University of Southern California Alzheimer Therapeutic Research Institute - San Diego (United States), ³C²N Diagnostics - St. Louis (United States), ⁴EISAI - Nutley (United States), ⁵University of Southern California, Alzheimer Clinical Trials Consortium - San Diego (United States)

10:35 a.m.

11:05 a.m.

Coffee Break — Poster Session and Rising Star Showcase

11:05 a.m.

11:45 a.m.

SYMPOSIUM 3

Remote Digital Biomarkers in Alzheimer's Disease Clinical Trials: From Scalable Prescreening to Sensitive AI-Enabled Assessment

Co-chairs: Gustavo A. Jimenez-Maggiora, Alzheimer's Therapeutic Research Institute (ATRI), Epstein Family Center for Alzheimer's Disease Research, Keck School of Medicine of USC, San Diego, CA – (United States)
Duygu Tosun, — University of California, San Francisco (UCSF) - San Francisco, CA (United States)

Presentation 1 The voice Clinical Dementia Rating® (vCDR) to facilitate clinical assessment for dementia research and trials using a generative AI powered conversational agent

Rachel L. Nosheny, University of California, San Francisco (UCSF) - San Francisco, CA (United States)

Presentation 2 Using digital multi-day learning curves for scalable early detection and tracking of subtle cognitive decline in preclinical AD

Kathryn V. Papp, Center for Alzheimer Research and Treatment, Brigham and Women's Hospital and Massachusetts General Hospital; Harvard Medical School - Boston, MA (United States)

Presentation 3 Real world feasibility, utility and generalizability of self-administered speech-based testing for scalable pre-screening for Mild Cognitive Impairment: results from the full ADNI4 digital cohort

Emil Fristed, Novoic Ltd.; Coagen Limited – London (United Kingdom)

11:45 a.m.

12:20 p.m.

BIOTECH SHOWCASE

Biotech Showcase and introductory panel

12:02 p.m.

BIOTECH SHOWCASE 1 Phase 2a AD Trial Results: NTRX-07 Reduces Neuroinflammation and Inhibits Neurodegeneration Following 28-days of Treatment

Joseph Foss¹, Marianna Kiraly¹, Peter Kovacs², Tony Giordano¹
¹NeuroTherapia, Inc. - Cleveland (United States), ²CRU Global - Budapest (Hungary)

12:08 p.m.

BIOTECH SHOWCASE 2 A Next-Generation circRNA Blood Biomarker Platform for Alzheimer's Disease Detection, Progression Prediction, and Clinical Deployment

Nikolaos Mellios¹, Bridget Phillips², Jessie Sanford², Vaibhav Janve³, Grigorios Papageorgiou³, John Morris², Joel Perlmutter², Paul Kotzbauer², Richard Perrin², Timothy Hohman³, Laura Ibanez², Carlos Cruchaga²

¹Circular Genomics - San Diego (United States), ²Washington University School of Medicine - St. Louis (United States), ³Vanderbilt University Medical Center - Nashville (United States)

12:14 p.m.

BIOTECH SHOWCASE 3 Sinaptica Therapeutics, Inc. ~ Precuneus-directed TMS-EEG precision-neuromodulation platform

Giacomo Koch^{1,2,3}

¹Sinaptica Therapeutics - Cambridge (United States), ²Santa Lucia Foundation IRCCS – Rome, Italy, ³University of Ferrara – Ferrara, Italy

12:20 p.m.

1:35 p.m.

Lunch and poster sessions

ORAL COMMUNICATIONS

1:35 p.m.

OC11 A Unified Timeline of Alzheimer's Disease: Linking Amyloid- β to Cognitive Decline

Rosita Shishegar¹, Timothy Cox², Marcela Cespedes³, Suzanne Schindler⁴, Tammie Benzinger⁵, Christopher C. Rowe⁶, Christopher J. Fowler⁷, Stephanie R. Rainey-Smith^{8, 9, 10}, Simon Laws¹¹, Mike Weiner¹², John Morris⁴, Colin L. Masters¹³, Hamid Sohrabi¹⁴, Paul Maruff¹⁵, James D. Doecke^{3, 11}

¹The Australian e-Health Research Centre, CSIRO - Parkville (Australia), ²The Australian e-Health Research Centre, CSIRO - Canberra (Australia), ³The Australian e-Health Research Centre, CSIRO - Herston (Australia), ⁴Department of Neurology, Washington University School of Medicine - St Louis (United States), ⁵Washington University School of Medicine - St Louis (United States), ⁶Austin Health - Heidelberg (Australia), ⁷The Florey Institute, The University of Melbourne - Parkville (Australia), ⁸Australian Alzheimer's Research Foundation - Perth (Australia), ⁹Centre for Precision Health and Collaborative Genomics Group, School of Medical and Health Sciences, Edith Cowan University - Joondalup, ¹⁰Centre for Healthy Ageing, Health Future Institute, Murdoch University - Murdoch, ¹¹Centre for Precision Health and Collaborative Genomics Group, School of Medical and Health Sciences, Edith Cowan University - Joondalup (Australia), ¹²University of California San Francisco, San Francisco, CA, USA; San Francisco Veterans Affairs Medical Center - San Francisco (United States), ¹³Alzheimer's Research Australia, University of Western Australia - Perth (Australia), ¹⁴Centre for Healthy Ageing, Health Future Institute, Murdoch University - Murdoch (Australia), ¹⁵Cogstate Ltd. - Parville (Australia)

1:50 p.m.

OC12 When Plasma ptau217 and A β PET Disagree: Factors Associated With Biomarker Concordance and Discordance Across Ethnoracial Groups

Mahnaz Shekari¹, Tessa Harrison¹, Yishu Chao¹, Robert Rissman², Sid O'Bryant³, Petersen Melissa⁴, William J Jagust¹, Susan M. Landau¹

¹University of California - Berkeley (United States), ²University of California - San Diego (United States), ³University of North Texas Health Science Center - Texas (United States), ⁴Institute for Translational Research, University of North Texas Health Science Center - Texas (United States)

2:05 p.m.

OC13 Lecanemab Treatment in Real-World Settings Across Multiple Countries: A Meta-Analysis on ARIA Rates and Safety Profiles in Clinical Practice

Samuel Dickson¹, John Whetten¹, Chenge Zhang¹, Suzanne Hendrix¹, Katherine Youmans-Kidder², Daryl Jones²

¹Pentara Corporation - Salt Lake City (United States), ²Eisai Inc. - Nutley (United States)

2:20 p.m.

OC14 Detecting cognitive decline in preclinical AD over 1.5 years using digital cognitive assessments

Hairin Kim¹, Mark Dubbelman¹, Lex Minto¹, Daniel Soberanes¹, Vivienne Lubbat¹, Dorene Rentz¹, Gad Marshall¹, Reisa Sperling¹, Laura Baker², Mark Espeland², Susan Landau³, Rebecca Amariglio¹, Kathryn Papp¹

¹Department of Neurology, Massachusetts General Hospital, Harvard Medical School - Boston (United States), ²Department of Internal Medicine, Wake Forest University School of Medicine - Winston-Salem (United States), ³Helen Wills Neuroscience Institute (SL), University of California - Berkeley (United States)

2:35 p.m.
3:15 p.m.

SYMPOSIUM 4

Neuroinflammation in Alzheimer's Disease: Targeting the NLRP3 Inflammasome and Neuroimmune Crosstalk

Chair: Malú Gámez Tansey, Neuroscience Research Institute, Indiana University School of Medicine – Indianapolis, IN (United States)

Presentation 1 Central-Peripheral Neuroimmune Crosstalk: Targeting Immune Dysfunction to Reduce Neurodegenerative Disease Progression

Malú Gámez Tansey, Neuroscience Research Institute, Indiana University School of Medicine – Indianapolis, IN (United States)

Presentation 2 NLRP3 regulates microglial immune and metabolic function in dementia

Róisín M. McManus, German Center for Neurodegenerative Diseases (DZNE), Venusberg Campus - Bonn (Germany)

Presentation 3 The NLRP3 inflammasome as a therapeutic target in Alzheimer's disease: biomarker, preclinical evidence and Phase I healthy participants' safety data of the oral inhibitor RG6434

Gennaro Pagano, F. Hoffmann-La Roche Ltd - Basel (Switzerland)

3:15 p.m.
4:15 p.m.

ORAL COMMUNICATIONS

3:15 p.m.

OC15 Treatment with Pepinemap, Anti-SEMA4D Blocking Antibody, Reduces a Unique Astrocyte Subset (Ast10) Correlated with Cognitive Decline and Associated Biomarkers of Synaptic Loss in People with Early-Stage AD

Elizabeth Evans¹, Terrence Fisher¹, Leslie Balch¹, Natacha Comandante-Lou², Vikas Mishra¹, John Leonard¹, Loretta Mueller¹, Alan Howell¹, Charlotte E. Teunissen³, Lisa Vermunt³, Anton Porsteinsson⁴, Hyun Keun Cho⁵, Howard H. Feldman⁵, Lon Scheider⁶, Maurice Zauderer¹

¹Vaccinex, Inc - Rochester (United States), ²Columbia University Irving Medical Center - New York (United States), ³Amsterdam UMC - Amsterdam (The Netherlands), ⁴University of Rochester, *on behalf of SIGNAL-AD investigators - Rochester (United States), ⁵University of California, San Diego - San Diego (United States), ⁶University of Southern California, Keck School of Medicine - Los Angeles (United States)

3:30 p.m.

OC16 Plasma Tau Isomerization at Residue D54 as a Scalable Biomarker of Brain Tau Aggregation in Early-Onset Alzheimer's Disease

Nicolas R. Barthelemy¹, Soumya Mukherjee¹, Yingxin He¹, Vitaliy Ovod¹, Kanta Horie¹, Rama Koppiseti¹, Ani Eloyan², Dustin B. Hammers³, Kelly N. Nudelman³, Maria C. Carrillo⁴, Bradford C. Dickerson⁵, Gil D. Rabinovici⁶, Liana G. Apostolova³, Randall J. Bateman¹, Jeffrey L. Dage¹

¹Washington University - St. Louis (United States), ²Brown University - Providence (United States), ³Indiana University - Indianapolis (United States), ⁴Alzheimer's Association - Chicago (United States), ⁵Harvard Medical School - Charlestown (United States), ⁶UCSF - San Francisco (United States)

3:45 p.m.

OC17 Preventing Dementia with Shingles Vaccination? Evidence from Quasi-Randomized Vaccine Rollouts

Richard Haarbarger¹, James Mbinta², Siu Yuat Wong¹, Alex Wang², Colin Simpson³, Noah Stegehuis¹, Till Baernighausen⁴, Greg Martin⁵, Yoram Barak⁶, Andrew Sporle³, Aliitasi Su'a-Tavalla², Pascal Geldsetzer¹

¹Stanford University - Stanford (United States), ²Victoria University - Wellington (New Zealand), ³University of Auckland - Auckland (New Zealand), ⁴Heidelberg University - Heidelberg (Germany), ⁵New Zealand Ministry of Health - Wellington (New Zealand), ⁶Dunedin School of Medicine - Dunedin (New Zealand)

4:00 p.m.

OC18 Metabolic-Inflammatory Burden Identifies Attenuated Responders to Lifestyle Intervention and Supports GLP-1RA Combination-Trial Design: Evidence from the FINGER study

Adrian Noriega De La Colina^{1,2,3}, Arvid Gollwitzer^{1,2}, Anna Matton^{4,5,6}, Francesca Mangialasche^{7,5,6}, Li-Huei Tsai^{1,8}, Alina Solomon^{6,4,9}, Tiia Ngandu^{6,9}, Giovanni Traverso^{1,2,3,10}, Miia Kivipelto^{4,5,11}

¹Broad Institute of MIT and Harvard - Cambridge (United States), ²Massachusetts Institute of Technology - Cambridge (United States), ³Brigham and Women's Hospital - Boston (United States), ⁴Division of Clinical Geriatrics, Centre for Alzheimer Research, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet - Solna (Sweden), ⁵Division of Neurogeriatrics, Centre for Alzheimer Research, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet - Solna (Sweden), ⁶FINGERS Brain Health Institute - Stockholm (Sweden), ⁷Division of Clinical Geriatrics, Centre for Alzheimer Research, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet - Solna (Sweden) - Solna (Sweden), ⁸The Picower Institute for Learning and Memory - Cambridge (United States), ⁹Institute of Clinical Medicine/Neurology, University of Eastern Finland - Kuopio (Finland), ¹⁰Koch Institute for Integrative Cancer Research, MIT - Cambridge (United States), ¹¹FINGERS Brain Health Institute - Stockholm (Sweden)

4:15 p.m.
4:45 p.m.

Coffee Break — Poster Session and Rising Star Showcase

4:45 p.m.
5:25 p.m.

LATE BREAKING SYMPOSIUM 1

Additional biomarker and clinical findings from the Phase 2 CELIA study of diranersen in early Alzheimer's disease

Adrian COLES, Jessica COLLINS, Gioacchino CURIALE, Amanda EDWARDS, Ellen HUANG, Melanie SHULMAN
Biogen, Cambridge, United States

● Wednesday, November 18

7:30 a.m.
8:30 a.m.

POSTER WALKING TOUR

8:30 a.m.
9:30 a.m.

ORAL COMMUNICATIONS

8:30 a.m.

OC19 Brain-Derived pTau217 Outperforms 328 Plasma Proteins for Association with Amyloid and Tau Accumulation and Cognitive Progression in the A4 and LEARN Studies

Robert RISSMAN¹, Michael DONOHUE¹, Joanne BEER², Clare PATERSON², Rema RAMAN¹, Sara ABDEL-LATIF¹, James BARLOW¹, Sahar SALEHI¹, Gustavo JIMENEZ-MAGGIORA¹, Richard GALLARDO¹, Keith JOHNSON³, Paul AISEN¹, Reisa SPERLING³

¹University of Southern California, San Diego, United States, ²Alamar Biosciences, Fremont, United States, ³Mass General Research Institute, Boston, United States

8:45 a.m.

OC20 Tau stable isotope labelling kinetics (SILK) and fluid biomarker response to NIO752 – tau MAPT antisense oligonucleotide: an unblinded interim analysis of a phase 1B trial in Alzheimer's disease

Aram ASLANYAN¹, Nicolas BARTHÉLEMY², Chihiro SATO², Don ELBERT³, Catherine MUMMERY¹, Lisa FRENCH¹, Guoqiao WANG², Nupur GHOSHAL², Eric MCADE², Randall BATEMAN², Ross PATERSON¹

¹UCL, London, United Kingdom, ²Washington University St Louis, St Louis, United States, ³University of Washington, Seattle, United States

9:00 a.m.

OC21 Psychosis symptoms associated with AD improve with short- and long-term open-label KarXT treatment

Jeffrey CUMMINGS¹, Ninoslav MIMICA², Ashish SHAH³, Janette GARNER³, Codrin LUNGU³, Antonio OLIVEROS-CID⁴, George GROSSBERG⁵

¹Kirk Kerkorian School of Medicine, University of Nevada at Las Vegas, Las Vegas, United States, ²University Psychiatric Hospital Vrapče and University of Zagreb School of Medicine, Zagreb, Croatia, ³Bristol Myers Squibb, Princeton, United States, ⁴Hospital Reina Sofía, Tudela, Spain, ⁵Saint Louis University School of Medicine, St. Louis, United States

9:15 a.m.

OC22 Estimating 15-Year absolute risk of cognitive impairment in cognitively unimpaired older adults with Alzheimer disease biomarkers based on amyloid PET or plasma %p-tau217

Sarah HARTZ¹, Lisa HAYIBOR¹, Shinjini KUNDU¹, Randall BATEMAN¹, Tammie BENZINGER¹, Brian GORDON¹, John MORRIS¹, Krista MOULDER¹, Jessica MOZERSKY¹, Kellen PETERSEN¹, Guoqiao WANG¹, Suzanne SCHINDLER¹, Walter KUKULL¹, Chengjie XIONG¹

Washington University, St. Louis, United States

9:30 a.m.
9:55 a.m.

KEYNOTE 3

Integration of Fluid Imaging and other Multimodal Biomarkers towards Optimizing Disease Understanding and New Therapeutics

Susan Landau, PhD, Research Neuroscientist, Helen Wills Neuroscience Institute University of California, Berkeley, CA (United States)

Introduction: Michael Weiner, University of California, San Francisco – San Francisco, CA (United States)

9:55 a.m.
10:25 a.m.

ORAL COMMUNICATIONS

Session on Study Design and Phase 1/Phase 2a Studies

9:55 a.m.

OC23 PreventRON: Evaluating the effect of trontinemab in cognitively unimpaired individuals with biomarkers of Alzheimer's disease at high risk of clinical decline

Reisa Sperling¹, Catherine Mummery², Jeffrey L. Cummings³, Gil Rabinovici⁴, Stephen Salloway⁵, Henrik Zetterberg⁶, Juan Fortea⁷, Frank G. Boess⁸, Christopher Lane⁹, Marion Monchalin⁸, Paul Delmar⁸, Luka Kulic⁸, Hanno Svoboda⁸, Geoffrey A. Kerchner⁸, Janice Smith⁹

¹Center for Alzheimer Research and Treatment, Brigham and Women's Hospital, Massachusetts General Hospital, Harvard Medical School - Boston (United States), ²Queen Square Institute of Neurology, University College London - London (United Kingdom), ³Chambers-Grundy Center for Transformative Neuroscience, Kirk Kerkorian School of Medicine, University of Nevada Las Vegas - Las Vegas (United States), ⁴Weill Institute for Neurosciences, Department of Radiology and Biomedical Imaging, University of California San Francisco - San Francisco (United States), ⁵Warren Alpert Medical School, Brown University - Providence (United States), ⁶Institute of Neuroscience and Physiology, Sahlgrenska Academy, University of Gothenburg - Mölndal (Sweden), ⁷Sant Pau Memory Unit, Neurology Department, Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute Sant Pau, Universitat Autònoma de Barcelona, Carrer de Sant Antoni Maria Claret - Barcelona (Spain), ⁸F. Hoffmann-La Roche Ltd - Basel (Switzerland), ⁹Roche Products Ltd - Welwyn Garden City (United Kingdom)

10:05 a.m.

OC24 Results of a Phase 1 Trial of Intracerebroventricular Injection of Autologous, Wnt-Activated, Adipose-Derived Stem Cells for Alzheimer's Disease; a First-in-Human Study

Christopher Duma¹, Jessica Buxton², Hans Keirstead³, Gabriel Nistor², Robert Lynn², Sawyer Farmer², Ashley Harris², Karlyssa Chung², Nathaniel Cho², Zoe Hareng², Jason Bock², Benjamin Rapaport², Gustavo Alva¹

¹Hoag Memorial Hospital - Newport Beach, CA (United States), ²Regeneration Biomedical, Inc. - Newport Beach, CA (United States), ³Aivita Biomedical, Inc. - Irvine, CA (United States)

10:15 a.m.

OC25 A phase 2 randomized, controlled trial of MK-2214, a novel antibody targeting pS413 tau, in early Alzheimer's disease: Study rationale and design

W. Joseph Herring¹, Yuchuan Wang¹, Li He¹, Yuki Mukai¹, Christine Furtek¹, Angela Gee¹, Andrei Popescu¹, Seth Robey¹, Michael F. Egan¹

¹Merck & Co., Inc. - Rahway, NJ (United States)

10:25 a.m.

11:00 a.m.

Coffee Break — Poster Session and Rising Star Showcase

11:00 a.m.

11:40 p.m.

SYMPOSIUM 5

Lecanemab Three Years Post-Approval: A Comprehensive Multicenter, Real-World, Retrospective Study (LEADER) in Diverse US Clinical Settings

Chair: Marwan Sabbagh, Barrow Neurological Institute - Phoenix, AZ (United States)

Presentation 1 Real-World Lecanemab Utilization and Outcomes from Initiation Through Maintenance Therapy in Early Alzheimer's Disease: A Multicenter Retrospective Study (LEADER)

Jose Soria, The Neuron Clinic - Chula Vista, CA (United States)

Presentation 2 Sex-Based Outcomes of Lecanemab in Early Alzheimer's Disease: A Multicenter, Real-World, Retrospective Study (LEADER)

Tinatín Chabrashvili, SUNY Upstate Medical University - New York, NY (United States)

Presentation 3 At-Home Subcutaneous Lecanemab Administration: A Multicenter, Real-World, Retrospective Study (LEADER)

Brent Berry, Minneapolis Clinic of Neurology - Minneapolis, MN (United States)

11:40 a.m.

12:25 p.m.

ORAL COMMUNICATIONS

11:40 a.m.

OC26 Using Plasma P-tau217 and APOE Genotype to Predict Onset of Symptoms of Alzheimer's Disease

Yuequan Xu¹, Tamil Gunasekaran¹, Yian Gu¹, Lawrence Honig¹, Jennifer Manly¹, Adam Brickman¹, Corinne Engelman², Sterling Johnson², David Bennett³, Sid O'Bryant⁴, Caghan Kizil¹, Badri Vardarajan¹, Richard Mayeux¹

¹Columbia University - New York (United States), ²University of Wisconsin-Madison - Madison (United States), ³Rush University - Chicago (United States), ⁴University of North Texas Health Science Center - Fort Worth (United States)

11:55 a.m.

OC27 AAV2-BDNF Gene Therapy in Alzheimer's Disease and Mild Cognitive Improvement Improves FDG-PET in Memory Circuitry

Yilong Ma¹, Gabriel Leger², Douglas Scharre³, Andrea Davis³, Kai Christman², Sara Rahman², Russell Lonser³, Krystof Bankiewicz³, David Eidelberg¹, Bradley Elder³, Mark Tuszynski²

¹Feinstein Institute for Medical Research - Manhasset, NY (United States), ²UC San Diego - La Jolla, CA (United States), ³Ohio State University - Columbus, OH (United States)

12:10 p.m.

OC28 Leveraging the Global Neurodegeneration Proteomics Consortium Dataset to Identify Plasma Proteomic Profiles Associated with Alzheimer's Disease Progression and Biological Endotypes

Jennifer Panlilio¹, Lydia Wu², Olga Kahn¹, Jennifer Hsiao-Nakamoto¹, Varsha Krish², Farhad Imam², Ilya Barshai³, Sergey Feldman³, Laura Nisenbaum⁴, Aishwarya Sukumar²

¹Diagnostics Accelerator, Alzheimer's Drug Discovery Foundation - New York (United States), ²Gates Ventures - Seattle (United States), ³Data Cowboys - Seattle (United States),

⁴Alzheimer's Drug Discovery Foundation - New York (United States)

12:25 p.m.

Lunch and Poster Sessions

1:40 p.m.

1:40 p.m.

3:25 p.m.

ORAL COMMUNICATIONS

1:40 p.m.

OC29 Prognostic value of plasma p-tau217 for short- and long-term risk of cognitive impairment

Marisa N. DENKINGER¹, Valentina GHISAYS^{1, 2}, Wagner S. BRUM¹, Geidy E. SERRANO¹, Adam MECCA³, Sylvia VILLENEUVE⁴, Pedro ROSA NETO⁵, Alexa PICHET BINETTE⁶, Rhoda AU⁷, Michael ALOSCO⁸, Elizabeth HEAD⁹, Sterling C. JOHNSON¹⁰, Eric M. REIMAN², Jessica B. LANGBAUM², Nicholas J. ASHTON^{1, 2}

¹Banner Sun Health Research Institute, Sun City, United States, ²Banner Alzheimer's Institute, Phoenix, United States, ³Department of Psychiatry, Yale School of Medicine, New Haven, United States, ⁴Douglas Research Centre, McGill University, Montreal, United States, ⁵Translational Neuroimaging Laboratory, Douglas Hospital, The McGill University Research Centre for Studies in Aging, McGill University, Montreal, United States, ⁶Institut Universitaire de Gériatrie de Montréal Research Center, Montreal, United States, ⁷Boston University's and National Heart, Lung, and Blood Institute's Framingham Heart Study Framingham, Boston, United States, ⁸Boston University CTE Center and Alzheimer's Disease Research Center, Boston University Chobanian & Avedisian School of Medicine, Boston, United States, ⁹University of California, Irvine School of Medicine, Irvine, United States, ¹⁰Wisconsin Alzheimer's Disease Research Center, University of Wisconsin, Madison, United States

1:55 p.m.

OC30 LM11A-31 reduces CSF levels of eMTBR-tau243: a retrospective analysis of a phase 2a safety and exploratory biomarker trial in mild-moderate Alzheimer's disease

Frank LONGO¹, Stephen MASSA², Taylor SCHMITZ³, Mark ADAMS⁴, Shin-Cheng TZENG⁴, Philip VERGHESE⁴, Hayley SHANKS³

¹Stanford University, Palo Alto, United States, ²SFVAHCS/UCSF, San Francisco, United States, ³Western University, London, Canada, ⁴C2N Diagnostics LLC, St Louis, United States

2:10 p.m.

OC31 Relative Impact of Multidomain Lifestyle Interventions on Cardiovascular Risk Factor Change and Cognition over 24 months in the U.S. POINTER TRIAL

Rachel A WHITMER¹, Iris LENG², Laura BAKER², Maria C CARRILLO³, Heather SNYDER³, Rema RAMAN⁴, Sarah FARIAS TOMASZEWSKI⁵, Mark ESPELAND²

¹University of California, Davis, United States, ²Wake Forest University, Winston Salem, United States, ³Medical and Scientific Relations, Alzheimer's Association, Chicago, United States, ⁴University of Southern California, Los Angeles, United States, ⁵University of California Davis, Davis, United States

2:25 p.m.

OC32 Calibrated age of onset for amyloid positivity from plasma %p-tau217 leads to better design and improved representation of Black Americans in Alzheimer disease clinical trials: Simpson's paradox

Chengjie XIONG¹, Ruijin LU¹, Jingqin LUO¹, Suzanne SCHINDLER¹, Tammie BENZINGER¹, David WOLK², Leslie SHAW², Carey GLEASON³, James LAH⁴, Reisa SPERLING⁵, Keith JOHNSON⁵, Erik ROBERSON⁶, Krista MOULDER¹, David HOLTZMAN¹, John MORRIS¹

¹Washington University, St. Louis, United States, ²University of Pennsylvania, Philadelphia, United States, ³University of Wisconsin, Madison, United States, ⁴Emory University, Atlanta, United States, ⁵Harvard University, Boston, United States, ⁶University of Alabama, Birmingham, United States

2:40 p.m.

OC33 Harmonizing plasma pTau217 across immunoassay platforms: the Unified pTau217 Score (Units)

Wagner S. Brum¹, Marisa N. Denkiner², Alpna Singh², Tainá Marques², Lennessa Mazo³, Rachael E. Wilson⁴, Ramiro Eduardo Rea Reyes⁴, Henrik Zetterberg⁵, Antoine Leuzy¹, Valentina Ghisays⁶, Reisa A. Sperling⁷, Eric M. Reiman⁶, Jessica B. Langbaum⁶, Sterling C. Johnson⁴, Nicholas J. Ashton⁶

¹ZRO Imaging - Santiago De Compostela (Spain), ²Banner Sun Health Research Institute - Sun City (United States), ³Arizona State University - Phoenix (United States), ⁴University of Wisconsin-Madison - Madison (United States), ⁵University of Gothenburg - Gothenburg (Sweden), ⁶Banner Alzheimer's Institute - Phoenix (United States), ⁷Harvard Medical School - Boston (United States)

2:55 p.m.

OC34 Rapamycin modulates disease-relevant processes in the central nervous system of patients with early Alzheimer's disease: data from PET, MRI and CSF with long-term follow-up

Jonas E. Svensson¹, Ruben Dörfel¹, Martin Schain², Martin Bolin¹, Simona Sacuiu¹, Göran Hagman¹, Anton Forsberg Morén¹, Miia Kivipelto¹, Sangram Nag¹, Pontus Plavén-Sigra¹

¹Karolinska Institutet - Stockholm (Sweden), ²Antaras Medical - Mölndal (Sweden)

3:10 p.m.

OC35 Longitudinal characterization of tau PET accumulation and spread anchored to amyloid and tau positivity timelines

Samira Maboudian¹, Karly Cody², William Coath¹, Julie Oomens¹, Jacob Morse¹, Hailey Bruzzone¹, Ramiro Rea Reyes¹, Matthew Zammit¹, Bradley Christian¹, Sanjay Asthana¹, Nathaniel Chin¹, Jessica Caldwell¹, Sterling Johnson¹, Tobey Betthausen¹

¹University of Wisconsin – Madison - Madison (United States), ²University of California San Francisco - San Francisco (United States)

3:25 p.m.
4:00 p.m.

Coffee break — Poster session and Rising Star Showcase

4:00 p.m.
5:00 p.m.

ORAL COMMUNICATIONS

4:00 p.m.

OC36 Beyond amyloid and tau: Hippocampal volume and cognitive performance in the AHEAD-345 Study screening cohort

Benjamin Zide¹, Aaron Schultz¹, Michael Properzi¹, Michael Rafii², Gustavo Jimenez-Maggiora², Michael Donohue², Oliver Langford², Paul Aisen², Jin Zhou³, Michael Irizzary³, Shobha Dhadda³, Keith Johnson¹, Rachel Buckley¹, Reisa Sperling⁴, On Behalf Of The Ahead 3-45 Study Team⁴

¹Center for Alzheimer Research and Treatment, Mass General Brigham, Harvard Medical School - Boston, Ma (United States), ²Epstein Alzheimer's Therapeutic Research Institute, University of Southern California - San Diego, Ca (United States), ³Eisai Inc. - Nutley, Nj (United States), ⁴AHEAD ³⁻⁴⁵ Study Team, Alzheimer Clinical Trials Consortium (United States)

4:15 p.m.

OC37 Comparison of MK6240, Flortaucipir, PI2620 and RO948 tau PET tracers and plasma pTau217 across the Alzheimer's disease continuum

Guilherme Povala¹, Bruna Bellaver¹, Pamela C. L. Ferreira¹, Firoza Z. Lussier¹, Livia Amaral¹, Juan Fortea², Thomas K. Karikari¹, David N. Soleimani-Meigooni³, Val J. Lowe⁴, Hwamee Oh⁵, Brian A. Gordon⁶, Belen Pascual⁷, Pedro Rosa-Neto⁸, Suzanne Baker⁹, Tharick A. Pascoal¹

¹University of Pittsburgh, Department of Psychiatry - Pittsburgh (United States), ²Sant Pau Memory Unit, IR SANT PAU, Hospital de la Santa Creu i Sant Pau - Barcelona (Spain), ³University of California San Francisco, Edward and Pearl Fein Memory and Aging Center - San Francisco (United States), ⁴Mayo Clinic, Department of Radiology - Rochester (United States), ⁵Brown University, Department of Psychiatry and Human Behavior - Providence (United States), ⁶Washington University in St. Louis, Department of Radiology - St. Louis (United States), ⁷Houston Methodist Research Institute and Weill Cornell Medicine, Department of Neurology - Houston (United States), ⁸Translational Neuroimaging Laboratory, McGill University Research Centre for Studies in Aging, Douglas Research Institute - Montréal (Canada), ⁹Lawrence Berkeley National Laboratory - Berkeley (United States)

4:30 p.m.

OC38 Characterization of US Real-World Patients Receiving Donanemab with Modified Titration Using the NeuroDiscovery AI Database

Cara Leahy¹, Drew Spargo², Erin Gautier Doty², J. Scott Andrews², Krista Marie Schroeder², Vamsi Chandra Kasivajjala³, Akash Bhushan⁴, Anand Kumar Srirampurapu⁴, Ann Hartry²

¹Memorial Healthcare Institute for Neuroscience - Owosso (United States), ²Eli Lilly and Company - Indianapolis (United States), ³NeuroDiscovery AI - Alpharetta (United States), ⁴NeuroDiscovery AI - Bangalore (India)

4:45 p.m.

OC39 Combining Plasma p-Tau217 with Proteomic Signatures Enables Graded Risk Stratification for Alzheimer's Disease Progression

Menghan Liu¹, Katherine Gong¹, Yike Chen¹, Ying Xu¹, Jigyasha Timsina¹, John Budde¹, John Morris¹, Marco Giorgetti², David Holtzman¹, Jeremiah Hinson², Scott Levin², Suzanne Schindler¹, Kausik Das², Muhammad Ali¹, Carlos Cruchaga¹

¹Washington University School of Medicine - St. Louis, MO (United States), ²Danaher Diagnostics - Washington DC (United States)

5:00 p.m.
5:20 p.m.

BIOTECH SHOWCASE

Biotech Showcase and introductory panel

5:02 p.m.

BIOTECH SHOWCASE 4 A First-in-Class CNS-Penetrant Small Molecule Targeting APOE4-mediated Neurovascular Dysfunction in Alzheimer's Disease

Caghan Kizil¹, Badri Vardarajan¹, Richard Mayeux¹

¹Department of Neurology, Columbia University Irving Medical Center - New York City (United States) Late breaking Biotech Showcase sessions

5:08 p.m.

BIOTECH SHOWCASE 5 Temporal Biodynamics: An AI Platform for Identification of Stage-Relevant Targets and Biomarkers

Sandra J. ENGLE¹, Joseph ZULLO¹, Joseph J. RAYMOND¹, Tanya JAIN¹, Michelle CHEN¹, Parth NATEKAR¹, Baixue YAO¹, Anna RUSNAK¹, Sachit SAKSENA², Artem SOKOLOV¹

¹Etiome, Cambridge, United States, ²Flagship Pioneering, Cambridge, United States

5:14 p.m.

BIOTECH SHOWCASE 6 Multimodal AI for early prediction and precision stratification in ADRD

Zoe KOURTZI¹, Felix BREACH¹, Tino PETER², Welchman ANDREW³

¹Univ Cambridge, Prodromic, Cambridge, United Kingdom, ²Univ of Birmingham, Birmingham, United Kingdom, ³Prodromic, Cambridge, United Kingdom

5:20 p.m.

End of the conference day

● Thursday, November 19

7:30 a.m.
8:30 a.m.

POSTER WALKING TOUR

8:30 a.m.
9:10 a.m.

SYMPOSIUM 6

Lessons from The Life's end Benefits of cannabidiol and tetrahydrocannabinol (LiBBY) Study: Efficacy, Implementation, and Future Therapeutic Development in Advanced Dementia

Chairs: Olga Brawman-Mintzer, *Medical University of South Carolina* and Ralph H. Johnson, *VA Health Care System - Charleston, SC (United States)*

Presentation 1 Domain-Specific Effects of THC/CBD on Agitation in Advanced Dementia: Cohen-Mansfield Agitation Inventory Analyses from the LiBBY Study Presentation

Jacobo Mintzer, *Medical University of South Carolina, Charleston, South Carolina (United States)*

Presentation 2 Effects of THC/CBD on NPI-Q Agitated Symptoms in Advanced Dementia: Results from the Double-Blind, Placebo-Controlled LiBBY Study

Brigid Reynolds, *Georgetown University, Washington, DC, United States*

Presentation 3 Advancing Trials in Dementia: Lessons from LiBBY and a Future Research Agenda for the Alzheimer's Clinical Trial Consortium (ACTC)

Paul Aisen, *University of Southern California, La Jolla, California (United States)*

9:10 a.m.
10:10 a.m.

ORAL COMMUNICATIONS

9:10 a.m.

OC40 Early versus delayed cognitive effects of donanemab and lecanemab in early Alzheimer's disease: 24-month real-world trajectories and drug-specific baseline predictors of response

Yuki Kujuro¹

¹*Tachikawa Hospital - Tokyo (Japan)*

9:25 a.m.

OC41 CNS-selective plasma p-tau217 accurately captures Alzheimer's disease pathology and progression

Xuemei Zeng¹, Marissa F. Farinas¹, Michel N. Nafash¹, Neelesh Nadkarni¹, C. Elizabeth Shaaban¹, Tharick A. Pascoal¹, Victor L. Villemagne¹, Beth E. Snitz¹, Milos D. Ikonovic¹, Julia K. Kofler¹, M. Ilyas Kamboh¹, Annie D. Cohen¹, Oscar L. Lopez¹, Thomas K. Karikari¹

¹*University of Pittsburgh - Pittsburgh (United States)*

9:40 a.m.

OC42 Understanding intermediate values in two-point thresholds for PET, CSF, and plasma biomarkers across cohorts and p-tau217 assays

Jacob Ziontz¹, Ganna Blazhenets¹, Zoe Lin¹, John Kornack¹, Susan Landau², Leslie Shaw³, Jeffrey Dage⁴, Dustin Hammers⁴, Ani Eloyan⁵, Robert Koeppe⁶, Maria Carrillo⁷, Bradford Dickerson⁸, Liana Apostolova⁴, Gil Rabinovici¹, Renaud La Joie¹

¹*University of California, San Francisco - San Francisco, CA (United States)*, ²*University of California, Berkeley - Berkeley, CA (United States)*, ³*University of Pennsylvania - Philadelphia, PA (United States)*, ⁴*Indiana University - Bloomington, IN (United States)*, ⁵*Brown University - Providence, RI (United States)*, ⁶*University of Michigan - Ann Arbor, MI (United States)*, ⁷*Alzheimer's Association - Chicago, IL (United States)*, ⁸*Massachusetts General Hospital - Boston, MA (United States)*

9:55 a.m.

OC43 Diagnostic Performance of the Fujirebio Lumipulse Plasma p-tau217 and p-tau217/Aβ42 Assays for Detection of Amyloid Pathology in Cognitively Unimpaired Individuals

Daniel Figdore¹, Jeremy Syrjanen¹, Joshua Bornhorst¹, Jonathan Graff-Radford¹, Prashanthi Vemuri¹, David Knopman¹, Clifford Jack¹, Ronald Petersen¹, Alicia Algeciras-Schimmich¹

¹*Mayo Clinic - Rochester (United States)*

10:10 a.m. 10:40 a.m.	Coffee Break — Poster Session and Rising Star Showcase
10:40 a.m. 11:05 a.m.	KEYNOTE 4 Beyond Amyloid and Tau: Roles of Proteomics in Clinical Trials <u>Allan Levey</u> , <i>Professor of Neurology, Emory University's School of Medicine, Emory's Alzheimer's Disease Research Center, Emory University - Atlanta, GA (United States)</i> Introduction: <u>Paul Aisen</u> , <i>ATRI-USC – La Jolla, CA (United States)</i>
11:05 a.m. 12:05 p.m.	ORAL COMMUNICATIONS
11:05 a.m.	OC44 The relationship between P-tau217 blood tests and neuropathology at autopsy in cognitively unimpaired individuals <u>Samantha BURNHAM</u> ¹ , <u>Amanda MORRIS</u> ¹ , <u>Marisa DENKINGER</u> ² , <u>Taina M. MARQUES</u> ² , <u>Alpana SINGH</u> ² , <u>Geidy SERRANO</u> ² , <u>Brandy R. MATTHEWS</u> ¹ , <u>Thomas BEACH</u> ² , <u>Mark MINTUN</u> ¹ , <u>Nicholas J. ASHTON</u> ² ¹ Eli Lilly and Company, Indianapolis, IN, USA, Indianapolis, United States, ² Banner Sun Health Research Institute, Sun City, AZ, USA, Sun City, United States
11:20 a.m.	OC45 When Is Amyloid Really Cleared? Discordance Between Centiloid Quantification and Visual Reads after Treatment <u>Renaud LA JOIE</u> , <u>Marlene LIN</u> , <u>Yingbing WANG</u> , <u>David SOLEIMANI-MEIGOONI</u> , <u>Tara ELLINGSON</u> , <u>Hong NGUYEN</u> , <u>Ganna BLAZHENETS</u> , <u>Corrina FONSECA</u> , <u>Jake LEVY</u> , <u>Julio ROJAS-MARTINEZ</u> , <u>Melanie STEPHENS</u> , <u>Nhat BUI</u> , <u>Peter LJUBENKOV</u> , <u>Lawren VANDEVREDE</u> , <u>Gil RABINOVICI</u> <i>UCSF, San Francisco, United States</i>
11:35 a.m.	OC46 Cognitive change across the healthy adult lifespan, ages 36 to 108: Associations with modifiable risk factors and ADRD plasma biomarkers <u>Steven ARNOLD</u> ¹ , <u>Pia KIVISÄKK</u> ¹ , <u>Chao-Yi WU</u> ¹ , <u>Edmarie GUZMAN-VELEZ</u> ² , <u>Brandon YATES</u> ¹ , <u>Yue HONG</u> ¹ , <u>Hrioko DODGE</u> ¹ , <u>David SALAT</u> ¹ ¹ Massachusetts General Hospital / Harvard Medical School, Boston, United States, ² Rutgers Institute for Health, Health Care Policy and Aging Research, New Brunswick, United States
11:50 a.m.	OC47 PROTECT-Cog: A Large, Global Randomized Phase 3 Trial of Combined Multidomain Lifestyle Intervention With and Without a Metabolic Targeting Drug to Benefit Cognitive Performance and Mitigate Decline in At-Risk Older Adults <u>Alireza ATRI</u> ¹ , <u>Laura D BAKER</u> ² , <u>Lucia CRIVELLI</u> ³ , <u>Mark ESPELAND</u> ² , <u>Miia KIVIPELTO</u> ⁴ , <u>Markku PELTONEN</u> ⁵ , <u>Rema RAMAN</u> ⁶ , <u>Heather M SNYDER</u> ⁷ , <u>Ari SOLOMAN</u> ⁸ , <u>Rachel A WHITMER</u> ⁹ , <u>Maria C CARRILLO</u> ⁷ ¹ Banner Research, Director of Banner Sun Health Research Institute, Sun City, United States, ² Department of Internal Medicine, Wake Forest University School of Medicine, Winston Salem, United States, ³ Department of Cognitive Neurology, FLENI, Buenos Aires, Argentina, ⁴ Division of Clinical Geriatrics, Center for Alzheimer Research, Karolinska Institute, Stockholm, Sweden, ⁵ Finnish Institute for Health and Welfare, Helsinki, Finland, ⁶ Epstein Family Alzheimer's Therapeutic Research Institute, University of Southern California, San Diego, United States, ⁷ Medical and Scientific Relations and Medical Affairs Division, Alzheimer's Association, Chicago, United States, ⁸ Institute of Clinical Medicine/Neurology, University of Eastern Finland, Kuopio, Finland, ⁹ Department of Public Health Sciences and Neurology, University of California, Davis, Davis, United States
12:05 p.m. 1:05 p.m.	Lunch and Poster Sessions
1:05 p.m. 3:50 p.m.	ORAL COMMUNICATIONS
1:05 p.m.	OC48 Dynamic changes in plasma biomarkers in patients treated with lecanemab: a longitudinal cohort study <u>Rui MU</u> , <u>Anna HOFMANN</u> , <u>Katherine GONG</u> , <u>Menghan LIU</u> , <u>Alex ROUSSAK</u> , <u>Madeline PACZYNSKI</u> , <u>Zachary POSEY</u> , <u>Aditi GUPTA</u> , <u>Tammie BENZINGER</u> , <u>David HOLTZMAN</u> , <u>John MORRIS</u> , <u>B.Joy SNIDER</u> , <u>Randall BATEMANN</u> , <u>Suzanne SCHINDLER</u> , <u>Carlos CRUCHAGA</u> <i>Washington University School of Medicine, Saint Louis, United States</i>

- 1:20 p.m. **OC49 ARO-MAPT, a Subcutaneously Delivered Shuttled siRNA Silencing Tau Production: Early Phase 1 Safety, Tolerability, and Pharmacodynamic Results in Healthy Volunteers**
Catherine MUMMERY¹, Rohit KATIAL², Saffron CALMAN-O'DONNELL², Roger CHANG³, Dylon CHEN³, Ian COHEN⁴, David JAKABEK⁵, Bruce BREW⁵, Emma DEVENNEY⁶, Richard BERGERON⁷, Ran FU³, Grigoriy SHEKHTMAN³, James HAMILTON³, Sharon COHEN⁴
¹University College London, London, United Kingdom, ²New Zealand Clinical Research, Auckland, New Zealand, ³Arrowhead pharmaceuticals, Pasadena, United States, ⁴Toronto Memory Programme, Toronto, Canada, ⁵St. Vincent's Hospital Sydney, Sydney, Australia, ⁶NeuRA, Randwick, Australia, ⁷The Memory Clinic, Montreal, Canada
- 1:35 p.m. **OC50 Lecanemab Treatment and α -Synuclein Co-Pathology in the Clarity AD CSF Substudy**
Kanta HORIE, Pallavi SACHDEV, Han YIN, Steven HERSCH, Lynn KRAMER, Shobha DHADDA, Michael IRIZARRY
Eisai Inc., Nutley, United States
- 1:50 p.m. **OC51 Plasma eMTBR-tau as a biomarker for chronic traumatic encephalopathy tau tangle neuropathology**
Annalise E. MINER¹, Thor D. STEIN¹, Ann C. MCKEE¹, Jesse MEZ¹, Breton M. ASKEN², Henrik ZETTERBERG³, Christopher J. NOWINSKI⁴, Jeremy A. TANNER⁵, Martha E. SHENTON⁶, Jeffrey L. CUMMINGS⁷, Eric M. REIMAN⁸, Robert A. STERN¹, Gil D. RABINOVIC⁹, Nicholas J. ASHTON⁸, Michael L. ALOSCO¹
¹Boston University CTE Center and Alzheimer's Disease Research Center, Boston University Chobanian & Avedisian School of Medicine, Boston, United States, ²Department of Clinical and Health Psychology, University of Florida, Gainesville, United States, ³Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden, ⁴Concussion & CTE Foundation, Boston, United States, ⁵Department of Neurology, Glenn Biggs Institute for Alzheimer's and Neurodegenerative Diseases, University of Texas Health San Antonio, San Antonio, United States, ⁶Psychiatry Neuroimaging Laboratory, Departments of Psychiatry and Radiology, Brigham and Women's Hospital, Harvard Medical School, Somerville, United States, ⁷Chambers-Grundy Center for Transformative Neuroscience, Department of Brain Health, Kirk Kerkorian School of Medicine, University of Nevada Las Vegas, Las Vegas, United States, ⁸Banner Alzheimer's Institute, Phoenix, United States, ⁹Edward & Pearl Fein Memory and Aging Center, Department of Neurology, Memory and Aging Center, University of California San Francisco, San Francisco, United States
- 2:05 p.m. **OC52 A proof of concept trial of MIB-626, a sirtuin-NAD⁺ activator, in mild Alzheimer's disease dementia**
Gad Marshall¹, Karol Pencina², Valentine Shang², Daniel Press³, Scott McGinnis⁴, Seth Gale⁴, Pamela Friedman⁴, Soyoung Lee⁴, Ricardo Salazar⁵, Brahyan Galindo Mendez⁴, Kirsten Glennon⁴, Danielle Lavey⁴, Alexander Lin¹, Shalender Bhasin²
¹Center for Clinical Spectroscopy, Department of Radiology, Brigham and Women's Hospital, Harvard Medical School – Boston, MA (United States), ²Section on Men's Health, Aging and Metabolism, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School – Boston, MA (United States), ³Division of Cognitive Neurology, Department of Neurology, Beth Israel Deaconess Medical Center, Harvard Medical School – Boston, MA (United States), ⁴Center for Alzheimer Research and Treatment, Brigham and Women's Hospital, Harvard Medical School – Boston, MA (United States), ⁵Division of Geriatric Psychiatry, Department of Psychiatry, Brigham and Women's Hospital, Harvard Medical School – Boston, MA (United States)
- 2:20 p.m. **OC53 Distinct baseline topographies and short-interval spatiotemporal spread of [18F]MK-6240 tau PET in preclinical AD**
Stephanie Doering^{1,2}, Praveen Honhar^{1,2}, Amal Tiss², Charles Chen^{1,2}, Elliott Slade², Emma Thibault², Jackson Thompson², Eva Pintucci², Alex Becker², Michelle Farrell², Reisa Sperling², Julie Price^{1,2}, Keith Johnson², Jessie Fanglu Fu^{1,2}
¹Athinoula A. Martinos Center for Biomedical Imaging - Charlestown, MA (United States), ²Massachusetts General Hospital, Harvard Medical School - Boston, MA (United States)
- 2:35 p.m. **OC54 Amyloid and Tau PET Biological Staging Across Ethnoracial Groups in a Multi-Cohort Alzheimer's Disease Study**
Andrzej Sokolowski¹, Karly Cody^{1,2}, Luciah Medina Guerra¹, Isha Sai¹, Emily Johns¹, Alaina Durant³, Derek Archer³, Raul Vintimilla⁴, Sid O'Bryant⁴, Timothy Hohman³, Christina Young^{5,6}, Elizabeth Mormino¹
¹Department of Neurology and Neurological Sciences, Stanford University – Stanford, CA (United States), ²Department of Neurology, University of California San Francisco - San Francisco, CA (United States), ³Vanderbilt Memory and Alzheimer's Center, Vanderbilt University Medical Center – Nashville, TN (United States), ⁴Institute for Translational Research University of North Texas Health Science Center, - Fort Worth, TX (United States), ⁵Department of Radiology, UC Davis – Davis, CA (United States), ⁶Department of Neurology, UC Davis, - Davis, CA (United States)
- 2:50 p.m. **OC55 Biomarker Associations and Outcome Performance in Preclinical Alzheimer Disease Trials**
Michael DONOHUE¹, Oliver LANGFORD¹, Philip INSEL², Rema RAMAN¹, Michael RAFII³, Reisa SPERLING⁴, Paul AISEN¹
¹USC Epstein Family Alzheimer's Therapeutic Research Institute, University of Southern California, San Diego, Ca, United States, ²Department of Psychiatry, University of California, San Francisco, San Francisco, Ca, United States, ³USC Epstein Family Alzheimer's Therapeutic Research Institute, University of Southern California - San Diego, Ca (United States), San Diego, Ca, United States, ⁴Center for Alzheimer Research and Treatment, Brigham and Women's Hospital, Massachusetts General Hospital, Harvard Medical School, Boston, Ma, United States
- 3:05 p.m. **OC56 [¹⁸F]MODAG-009 PET imaging of alpha-synuclein pathology in the presence of amyloid-beta and tau co-pathology across the AD-DLB spectrum**
Armin GIESE¹, Daniel BLEHER², Ann-Kathrin GROTEGERD², Felix SCHMIDT¹, Daniel WECKBECKER¹, Andrei LEONOV¹, Sergey RYAZANOV¹, Viktoria RUF³, Andreas MAURER⁴, Christian GRIESINGER⁵, Ken MAREK⁶, Roger GUNN⁷, Johannes LEVIN¹, Matthias BRENDEL⁸, Kristina HERFERT²
¹MODAG GmbH, Wendelsheim, Germany, ²University of Tübingen, Tübingen, Germany, ³Ludwig-Maximilians-University, München, Germany, ⁴HZDR, Dresden, Germany, ⁵MPI Multidisciplinary Sciences, Göttingen, Germany, ⁶Institute for Neurodegenerative Disorders, New Haven, United States, ⁷XingImaging, New Haven, United States, ⁸Klinikum der Universität München, München, Germany

3:20 p.m.	OC57 Cross-platform performance of plasma p-tau217 assays for predicting amyloid PET positivity across cohorts <u>Sonal SUKREET</u>¹, Jennifer NGOLAB¹, Michael C. DONOHUE¹, Oliver LANGFORD¹, Rema RAMAN¹, Sara ABDEL-LATIF¹, Gustavo A. JIMENEZ-MAGGIORA¹, Michael S. RAFII¹, Hartmuth C. KOLB², Sterling C. JOHNSON³, Jasmeer CHATWAL⁴, Keith A. JOHNSON⁴, Paul S. AISEN¹, Reisa A. SPERLING⁴, Robert A. RISSMAN¹ ¹Epstein Family Alzheimer's Therapeutic Research Institute, San Diego, United States, ²Enigma Biomedical Group, San Diego, United States, ³University of Wisconsin, Wisconsin, United States, ⁴Harvard Medical School, Boston, United States
3:35 p.m.	OC58 Plasma p-tau217 and Aβ42/Aβ40 provide complementary information about amyloid PET below 20 Centiloids: Baseline findings from the Amyloid Plasma Extension Study <u>Doris MOLINA-HENRY</u>¹, Andy LIU¹, Oliver LANGFORD¹, Michael DONOHUE¹, Rema RAMAN¹, Joel BRAUNSTEIN², Gustavo JIMENEZ-MAGGIORA¹, Robert RISSMAN¹, Keith JOHNSON², Paul AISEN¹, Reisa SPERLING² ¹USC Epstein Family Alzheimer's Therapeutic Research Institute, San Diego, United States, ²Massachusetts General Hospital and Brigham and Women's Hospital, Harvard Medical School, Boston, United States
3:50 p.m. 4:10 p.m.	BIOTECH SHOWCASE Biotech Showcase and introductory panel
3:52 p.m.	BIOTECH SHOWCASE 7 Restoring Proteostasis in Alzheimer's Disease with Buntanetap, a Small-Molecule Translational Inhibitor of Neurotoxic Proteins <u>Alexander MORIN</u>, <u>Maria MACCECCHINI</u> <i>Annovis Bio, Malvern, United States</i>
3:58 p.m.	BIOTECH SHOWCASE 8 In silico simulation of clinical trials for Alzheimer's disease and related dementias <u>Min Gyeong KIM</u>¹, Yeong-Hun SONG^{1,2}, Yeon-Jeong LEE¹, Jeong-Yeon SONG¹, Junseo LEE^{1,3}, Euijeong SONG¹, Soohyun PARK¹, Seok HONG^{1,2}, Ahyun CHOI^{1,2}, Joon-Kyung SEONG^{1,2,3}, Wha Jin LEE¹ ¹Neuroxt, Inc., Seoul, Korea, Republic of, ²Department of Artificial Intelligence, Korea University, Seoul, Korea, Republic of, ³School of Biomedical Engineering, Korea University, Seoul, Korea, Republic of
4:04 p.m.	BIOTECH SHOWCASE 9 iMediSync Inc. — iSB-M: AI-based QEEG Biomarker Platform for Alzheimer's Disease and Lewy Body Comorbidity <u>Seung Wan KANG</u>¹, Nam Heon KIM¹, Jun Yeop KIM¹, Daekeun KIM¹, Dong Won YANG², Seong Hye CHOI³, Young Chul YOUN⁴, Byoung Seok YE⁵ ¹iMediSync, Inc., Seoul, Korea, Republic of, ²The Catholic University of Korea, Seoul, Korea, Republic of, ³Inha University School of Medicine, Incheon, Korea, Republic of, ⁴Chung-Ang University College of Medicine, Seoul, Korea, Republic of, ⁵Yonsei University College of Medicine, Seoul, Korea, Republic of
4:10 p.m.	End of the conference